ArticleFrontiers in immunology2026
The TIF-1γ autoantigen in patients with dermatomyositis and thyroid cancer: from case series to preliminary mechanistic exploration.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to explore the relationship between dermatomyositis (DM) and thyroid cancer and the role of transcriptional intermediary factor 1γ (TIF-1γ) in the pathogenesis of cancer-associated DM. Methods: Five cases of DM with thyroid cancer, including one with metastasis, were summarized and analyzed. Published cases of DM with thyroid cancer were reviewed. Subsequently, a bidirectional two-sample Mendelian randomization (MR) analysis was performed to investigate the relationship between thyroid cancer and myositis using inverse-variance weighting (IVW), MR-Egger, and weighted-median (WM) analyses. Finally, immunohistochemistry (IHC) and immunofluorescence (IF) analysis were performed to detect TIF-1γ in tumor tissues of a DM patient and a thyroid cancer patient without DM. Results: This article reports the first case of a patient with DM and metastatic papillary thyroid carcinoma (PTC), in whom recurrence of the rash prompted the detection of metastasis, with the rash resolving after surgical resection of the metastatic foci. MR analysis showed a potential causal relationship between thyroid cancer and myositis (OR = 1.398; 95% CI = 1.045-1.869; Conclusions: DM symptoms might represent a paraneoplastic phenomenon in patients with thyroid cancer, with the underlying pathological mechanisms requiring further exploration and TIF-1γ overexpression potentially serving as a trigger.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.